CGTN covers China and the world. We focus on nations, regions and people that are often passed over by other international media. Watch for free anytime. Subscribe for updates. No monthly fee. Available on multiple devices. View All ›. Watch CGTN anywhere! Available on multiple devices. View All ›. Watch for free anytime. Subscribe for updates.

Get the news as it breaks and go behind the day's top stories, from politics, business, culture and sports to nature, travel and technology. CGTN delivers a Chinese perspective on global news through innovative use of the latest media tools.

ChatGPT helps you get answers, find inspiration and be more productive. It is free to use and easy to try. Just ask and ChatGPT can help with writing, learning, brainstorming and more.

China Global Television Network, or CGTN, is an international media organization launched on December 31, 2016. It aims to provide global audiences with accu...

Focuses on China’s politics and governance, the CPC’s rule, and other sensitive China issues. The weekly program targets China watchers, experts, and policymakers globally by telling China’s inside, complex story through intimate, informed discussions with China’s thought leaders and decision makers, many of whom do not appear in foreign media.

Watch: Is Chinese wisdom the key for a better global governance?

After a heated exchange between Donald Trump and Ukraine's Volodmyr Zelenskyy on Feb. 28, and a pause in US aid to Ukraine, what's next? What now for Zelenskyy and Trump? 25% tariffs are being imposed on Canadian goods and retaliatory tariffs are likely. What's next?

Join us in uncovering the untold tales that influence our collective future in "Americas Now." Discover the richness, variety, and vitality of the Americas in a whole new way. Every story is a journey, and every journey is an adventure.

针对cgt领域慢病毒载体生产的一系列难题，深研生物创新性开发了基于稳定生产细胞株大规模生产慢病毒载体的 eulv ® 系统，一举突破世界性技术难题，是世界上第一个商业化无需质粒瞬时转染的慢病毒载体生产系统，为中国细胞基因治疗行业领先世界助力。

2024年10月24日 · 近年来，细胞与基因治疗 (CGT)的全球发展形势呈现出积极的增长态势，据 ASCGT 数据，全球 3633 项 CGT 临床试验中，2024项为基因治疗管线，803 项为不涉及基因编辑的细胞治疗管线。 中国也不遑多让，推动进行了 726 项试验。 从全球 CGT在研药物适应症分布来看，肿瘤和罕见病药物位居前列。 据市场研究机构测算，2016-2020 年，全球基因与细胞治疗市场规模年复合增长率达 153.3%，预计到 2025 年，市场规模有望达到 305.39 亿美元。 近些 …